SIRPA and neoplasm: Blockage of the CD47/SIRPα stimulates phagocytosis of cancer cells by macrophages in vitro and inhibits tumor growth in vivo.33 Therefore, we used therapeutic SIRPα antibodies to treat AOM-DSS-induced CRC.